Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 127Breast Neoplasms 127Ovarian Neoplasms 79Fallopian Tube Neoplasms 45Lung Neoplasms 42Carcinoma, Ovarian Epithelial 30Uterine Cervical Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 27Endometrial Neoplasms 25Triple Negative Breast Neoplasms 23Neoplasm Metastasis 21Neoplasms 20Esophageal Neoplasms 19Stomach Neoplasms 18Esophageal Squamous Cell Carcinoma 15Adenocarcinoma of Lung 13Carcinoma 12Brenner Tumor 11Recurrence 10Urinary Bladder Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 8Peritoneal Neoplasms 7Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma, Bronchiolo-Alveolar 5Adenocarcinoma 5Melanoma 4Carcinoma, Ductal, Breast 4Adenocarcinoma Of Esophagus 4

Interventions

Taxes 1Paclitaxel 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Adenocarcinoma, Mucinous × Paclitaxel × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡